Last reviewed · How we verify
Albis Tab
Albis Tab is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD.. It is currently FDA-approved.
At a glance
| Generic name | Albis Tab |
|---|---|
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of ALBIS on Gastroduodenal Mucosal Injury in Patients Receiving Dual Antiplatelet Therapy After Percutaneous Coronary Intervention (PHASE4)
- The Safety and Efficacy of Albis®: The Prevention of Aspirin-induced Gastrointestinal Ulcers in Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albis Tab CI brief — competitive landscape report
- Albis Tab updates RSS · CI watch RSS
- Daewoong Pharmaceutical Co. LTD. portfolio CI
Frequently asked questions about Albis Tab
What is Albis Tab?
Albis Tab is a Small molecule drug developed by Daewoong Pharmaceutical Co. LTD..
Who makes Albis Tab?
Albis Tab is developed and marketed by Daewoong Pharmaceutical Co. LTD. (see full Daewoong Pharmaceutical Co. LTD. pipeline at /company/daewoong-pharmaceutical-co-ltd).
What development phase is Albis Tab in?
Albis Tab is FDA-approved (marketed).
Related
- Manufacturer: Daewoong Pharmaceutical Co. LTD. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing